Literature DB >> 26001312

The choreography of neuroinflammation in Huntington's disease.

Andrea Crotti1, Christopher K Glass2.   

Abstract

Currently, the concept of 'neuroinflammation' includes inflammation associated with neurodegenerative diseases, in which there is little or no infiltration of blood-derived immune cells into the brain. The roles of brain-resident and peripheral immune cells in these inflammatory settings are poorly understood, and it is unclear whether neuroinflammation results from immune reaction to neuronal dysfunction/degeneration, and/or represents cell-autonomous phenotypes of dysfunctional immune cells. Here, we review recent studies examining these questions in the context of Huntington's disease (HD), where mutant Huntingtin (HTT) is expressed in both neurons and glia. Insights into the cellular and molecular mechanisms underlying neuroinflammation in HD may provide a better understanding of inflammation in more complex neurodegenerative disorders, and of the contribution of the neuroinflammatory component to neurodegenerative disease pathogenesis.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Huntington's disease; astrocytes; macrophages; microglia; neuroinflammation

Mesh:

Substances:

Year:  2015        PMID: 26001312      PMCID: PMC4786070          DOI: 10.1016/j.it.2015.04.007

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  103 in total

1.  Biochemical abnormalities and excitotoxicity in Huntington's disease brain.

Authors:  S J Tabrizi; M W Cleeter; J Xuereb; J W Taanman; J M Cooper; A H Schapira
Journal:  Ann Neurol       Date:  1999-01       Impact factor: 10.422

Review 2.  Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling.

Authors:  Sue Goo Rhee; Ho Zoon Chae; Kanghwa Kim
Journal:  Free Radic Biol Med       Date:  2005-03-24       Impact factor: 7.376

3.  Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors.

Authors:  Andrea Crotti; Christopher Benner; Bilal E Kerman; David Gosselin; Clotilde Lagier-Tourenne; Chiara Zuccato; Elena Cattaneo; Fred H Gage; Don W Cleveland; Christopher K Glass
Journal:  Nat Neurosci       Date:  2014-03-02       Impact factor: 24.884

4.  Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.

Authors:  Sara Valdeolivas; Valentina Satta; Roger G Pertwee; Javier Fernández-Ruiz; Onintza Sagredo
Journal:  ACS Chem Neurosci       Date:  2012-02-09       Impact factor: 4.418

5.  Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells.

Authors:  Wen Yang; John R Dunlap; Richard B Andrews; Ronald Wetzel
Journal:  Hum Mol Genet       Date:  2002-11-01       Impact factor: 6.150

6.  Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease.

Authors:  Han-Yun Hsiao; Feng-Lan Chiu; Chiung-Mei Chen; Yih-Ru Wu; Hui-Mei Chen; Yu-Chen Chen; Hung-Chih Kuo; Yijuang Chern
Journal:  Hum Mol Genet       Date:  2014-04-03       Impact factor: 6.150

Review 7.  Neuroinflammation in Alzheimer's disease.

Authors:  Michael T Heneka; Monica J Carson; Joseph El Khoury; Gary E Landreth; Frederic Brosseron; Douglas L Feinstein; Andreas H Jacobs; Tony Wyss-Coray; Javier Vitorica; Richard M Ransohoff; Karl Herrup; Sally A Frautschy; Bente Finsen; Guy C Brown; Alexei Verkhratsky; Koji Yamanaka; Jari Koistinaho; Eicke Latz; Annett Halle; Gabor C Petzold; Terrence Town; Dave Morgan; Mari L Shinohara; V Hugh Perry; Clive Holmes; Nicolas G Bazan; David J Brooks; Stéphane Hunot; Bertrand Joseph; Nikolaus Deigendesch; Olga Garaschuk; Erik Boddeke; Charles A Dinarello; John C Breitner; Greg M Cole; Douglas T Golenbock; Markus P Kummer
Journal:  Lancet Neurol       Date:  2015-04       Impact factor: 44.182

8.  Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease.

Authors:  Wanda Kwan; Anna Magnusson; Austin Chou; Anthony Adame; Monica J Carson; Shinichi Kohsaka; Eliezer Masliah; Thomas Möller; Richard Ransohoff; Sarah J Tabrizi; Maria Björkqvist; Paul J Muchowski
Journal:  J Neurosci       Date:  2012-01-04       Impact factor: 6.167

9.  Investigation into the role of macrophages in the formation and degradation of beta2-microglobulin amyloid fibrils.

Authors:  Isobel J Morten; Walraj S Gosal; Sheena E Radford; Eric W Hewitt
Journal:  J Biol Chem       Date:  2007-08-08       Impact factor: 5.157

10.  Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease.

Authors:  Xiaofeng Gu; Véronique M André; Carlos Cepeda; Shi-Hua Li; Xiao-Jiang Li; Michael S Levine; X William Yang
Journal:  Mol Neurodegener       Date:  2007-04-30       Impact factor: 14.195

View more
  72 in total

1.  Early immune responses are independent of RGC dysfunction in glaucoma with complement component C3 being protective.

Authors:  Jeffrey M Harder; Catherine E Braine; Pete A Williams; Xianjun Zhu; Katharine H MacNicoll; Gregory L Sousa; Rebecca A Buchanan; Richard S Smith; Richard T Libby; Gareth R Howell; Simon W M John
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-26       Impact factor: 11.205

2.  Methylphenidate Attenuates the Cognitive and Mood Alterations Observed in Mbnl2 Knockout Mice and Reduces Microglia Overexpression.

Authors:  Carla Ramon-Duaso; Thomas Gener; Marta Consegal; Cristina Fernández-Avilés; Juan José Gallego; Laura Castarlenas; Maurice S Swanson; Rafael de la Torre; Rafael Maldonado; M Victoria Puig; Patricia Robledo
Journal:  Cereb Cortex       Date:  2019-07-05       Impact factor: 5.357

Review 3.  Molecular insights into cortico-striatal miscommunications in Huntington's disease.

Authors:  Matthew B Veldman; X William Yang
Journal:  Curr Opin Neurobiol       Date:  2017-11-07       Impact factor: 6.627

4.  Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease.

Authors:  Joshua D Crapser; Joseph Ochaba; Neelakshi Soni; Jack C Reidling; Leslie M Thompson; Kim N Green
Journal:  Brain       Date:  2020-01-01       Impact factor: 13.501

5.  Selected health and lifestyle factors, cytosine-adenine-guanine status, and phenoconversion in Huntington's disease.

Authors:  Caroline Tanner; Karen Marder; Shirley Eberly; Kevin Biglan; David Oakes; Ira Shoulson
Journal:  Mov Disord       Date:  2018-01-03       Impact factor: 10.338

6.  High-Throughput Functional Analysis Distinguishes Pathogenic, Nonpathogenic, and Compensatory Transcriptional Changes in Neurodegeneration.

Authors:  Ismael Al-Ramahi; Boxun Lu; Simone Di Paola; Kaifang Pang; Maria de Haro; Ivana Peluso; Tatiana Gallego-Flores; Nazish T Malik; Kelly Erikson; Benjamin A Bleiberg; Matthew Avalos; George Fan; Laura Elizabeth Rivers; Andrew M Laitman; Javier R Diaz-García; Marc Hild; James Palacino; Zhandong Liu; Diego L Medina; Juan Botas
Journal:  Cell Syst       Date:  2018-06-20       Impact factor: 10.304

7.  Inhibition of NF-κB in astrocytes is sufficient to delay neurodegeneration induced by proteotoxicity in neurons.

Authors:  Y X Li; O C M Sibon; P F Dijkers
Journal:  J Neuroinflammation       Date:  2018-09-11       Impact factor: 8.322

8.  Pyruvate blocks blood-brain barrier disruption, lymphocyte infiltration and immune response in excitotoxic brain injury.

Authors:  Jae K Ryu; James G McLarnon
Journal:  Am J Neurodegener Dis       Date:  2016-03-01

9.  Adrenergic Signaling in Muscularis Macrophages Limits Infection-Induced Neuronal Loss.

Authors:  Fanny Matheis; Paul A Muller; Christina L Graves; Ilana Gabanyi; Zachary J Kerner; Diego Costa-Borges; Tomasz Ahrends; Philip Rosenstiel; Daniel Mucida
Journal:  Cell       Date:  2020-01-09       Impact factor: 41.582

Review 10.  Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system.

Authors:  Ruiqing Ni; Linjing Mu; Simon Ametamey
Journal:  Acta Pharmacol Sin       Date:  2018-06-19       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.